查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970930

喉癌治療市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、最終用戶、地區和競爭對手分類，2021-2031年

Laryngeal Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球喉癌治療市場預計將從 2025 年的 40.9 億美元成長到 2031 年的 53.6 億美元，複合年成長率為 4.61%。

此領域涵蓋用於治療喉部惡性腫瘤的藥物和生物製藥。市場成長的主要促進因素是全球頭頸癌發病率的上升（通常與長期吸煙和飲酒有關）以及標靶免疫療法的廣泛應用。例如，美國癌症協會估計，到2025年，美國將新增約13,020例喉癌。

市場概覽
預測期 2027-2031
市場規模：2025年 40.9億美元
市場規模：2031年 53.6億美元
複合年成長率：2026-2031年 4.61%
成長最快的細分市場 生物製藥
最大的市場 北美洲

然而，新型治療方法的高昂成本是市場擴張的一大障礙。先進生物製藥和免疫查核點抑制劑帶來的沉重經濟負擔限制了患者的藥物機會，尤其是在發展中地區。這種經濟壁壘構成了一項重大挑戰，可能限制這些先進治療方法的普及，並阻礙其在全球市場的更廣泛成長和滲透。

市場促進因素

全球喉癌發生率的不斷上升是推動市場發展的主要因素，這主要歸因於吸煙和飲酒等高風險行為。日益加重的患者負擔凸顯了對有效藥物治療方案的需求，並推動了對傳統化療和新興生物療法的需求。國際衛生預測凸顯了這一情況的迫切性。例如，國際癌症研究機構（IARC）在2024年2月發布的新聞稿中預測，到2050年，新增癌症病例將激增77%，強調了長期持續供應治療藥物以應對日益成長的疾病負擔的必要性。

此外，免疫療法和標靶治療的進步顯著推動了市場發展，大大改善了轉移性或復發性疾病患者的臨床療效。製藥公司正大力投資研發，以推出免疫查核點抑制劑，與標準細胞毒性療法相比，這些抑制劑能夠提高病患的存活率。這些先進治療方法的商業性成功體現在其快速普及應用上。 2024年2月，默克公司報告稱，Keytruda的全球銷售額在2023年成長了19%，達到250億美元。患者數量的持續成長進一步支撐了這一成長趨勢，美國國家癌症研究所估計，2024年美國將新增12,630例喉癌病例。

市場挑戰

新型治療方法的高昂費用對全球喉癌治療市場構成重大挑戰。先進療法，尤其是免疫查核點抑制劑和生物目標製劑，其價格遠高於傳統的放射線治療和化療通訊協定。這種價格差異對中低收入國家的患者而言構成了一道難以克服的障礙，因為這些國家的醫療體系往往不足以涵蓋這些昂貴的藥物。因此，在對成本高度敏感的地區，這些療法的普及率受到抑制，收入潛力也受到限制。

此外，這些昂貴治療帶來的經濟負擔迫使許多患者推遲或放棄必要的治療，實際上縮小了接受治療的患者群體。根據美國癌症協會預測，到2024年，約60%的適齡癌症倖存者將面臨經濟困難，例如難以支付醫療費用或因費用問題而延誤治療。這種經濟負擔極大地限制了進行性喉癌治療的實際普及程度，使很大一部分目標人口無法獲得治療，並阻礙了治療市場的整體成長。

市場趨勢

新輔助免疫療法通訊協定的興起正在重塑全球市場格局，其方法是在局部晚期癌症患者接受手術治療前引入免疫查核點抑制劑。這種策略旨在降低腫瘤分期並清除微轉移灶，與傳統的放射線治療方案相比，可顯著延長患者的無無惡化存活期。隨著新數據證實新輔助免疫療法能夠在不延遲根治性手術的情況下改善治療效果，其臨床應用正在加速。華盛頓大學醫學院2025年4月發布的報告顯示，接受Pembrolizumab合併標準療法治療的患者，其中位無癌症存活期為51.8個月，而僅接受標準療法的患者中位無癌症存活期為30.4個月。

同時，針對HPV相關病例，在降低治療強度方面也取得了進展，旨在減少預後良好患者的治療相關併發症。腫瘤科醫師正利用生物標記篩選適合降低放射線治療和化療強度的患者，在維持高治癒率的同時，最大限度地減少吞嚥困難等長期毒性。鑑於目前病毒性惡性腫瘤的發生率遠高於菸草相關病例，這種個人化治療方法顯得特別重要。美國疾病管制與預防中心（CDC）在2025年12月報告稱，每年將新增約49,908例HPV相關癌症病例，這凸顯了此類器官保留治療方法的市場需求不斷成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：喉癌治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（生物製藥、小分子化合物）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美喉癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲喉癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區喉癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲喉癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美喉癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球喉癌治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Johnson & Johnson
  • Cipla Ltd
  • Abbott Laboratories Inc
  • AbbVie Inc
  • Merck KGaA
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Lupin Ltd
  • Pfizer Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19044

The Global Laryngeal Cancer Therapeutics Market is projected to expand from USD 4.09 Billion in 2025 to USD 5.36 Billion by 2031, registering a compound annual growth rate of 4.61%. This sector comprises pharmaceutical and biologic interventions developed to treat malignant neoplasms originating in the larynx. The market's growth is primarily fueled by the increasing global incidence of head and neck carcinomas, which are often linked to prolonged tobacco and alcohol use, as well as the rising utilization of targeted immunotherapies. For instance, the American Cancer Society estimated that approximately 13,020 new cases of laryngeal cancer would be diagnosed in the United States in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.09 Billion
Market Size 2031USD 5.36 Billion
CAGR 2026-20314.61%
Fastest Growing SegmentBiologics
Largest MarketNorth America

However, market expansion faces a substantial hurdle due to the exorbitant costs associated with novel treatment regimens. The significant financial load imposed by advanced biologic drugs and immune checkpoint inhibitors restricts patient access, particularly in developing regions. This economic barrier limits the reach of these sophisticated treatments and creates a formidable challenge that could inhibit the broader growth and penetration of the global market.

Market Driver

The increasing global prevalence of laryngeal carcinoma acts as a primary catalyst for the market, largely stemming from high-risk behaviors such as tobacco use and alcohol consumption. This rising patient burden necessitates the procurement of effective pharmacological solutions, thereby boosting demand for both traditional chemotherapies and emerging biological treatments. The urgency of this situation is highlighted by international health projections; for example, the International Agency for Research on Cancer predicted in a February 2024 press release that new cancer cases would surge by 77 percent by 2050, emphasizing the long-term need for a sustained therapeutic supply to manage this growing disease load.

Additionally, advancements in immunotherapy and targeted therapeutics are significantly driving the market by transforming clinical outcomes for patients with metastatic or recurrent disease. Pharmaceutical companies are investing heavily in research and development to introduce immune checkpoint inhibitors that improve survival rates compared to standard cytotoxic regimens. The commercial success of these advanced modalities is evident in their rapid adoption; Merck & Co., Inc. reported in February 2024 that global sales of Keytruda increased by 19 percent to 25.0 billion dollars in 2023. This trajectory is further supported by steady patient volumes, with the National Cancer Institute estimating 12,630 new laryngeal cancer diagnoses in the United States in 2024.

Market Challenge

The prohibitive cost of novel treatment regimens presents a major challenge to the Global Laryngeal Cancer Therapeutics Market. Advanced therapies, specifically immune checkpoint inhibitors and targeted biologics, are priced considerably higher than traditional radiation and chemotherapy protocols. This price disparity establishes a significant barrier to entry for patients in low- and middle-income nations, where healthcare reimbursement systems are frequently inadequate to cover these premium pharmaceuticals, consequently suppressing adoption rates and limiting revenue potential in cost-sensitive regions.

Furthermore, the financial toxicity associated with these high-cost regimens forces many patients to delay or forego necessary care, effectively shrinking the active consumer base. According to the American Cancer Society, in 2024, nearly 60% of working-age cancer survivors reported experiencing financial hardship, such as difficulty paying medical bills or delaying treatment due to cost. This economic strain severely restricts the practical reach of advanced laryngeal cancer drugs, rendering them inaccessible to a large segment of the target population and hampering the overall growth trajectory of the therapeutics market.

Market Trends

The rise of Neoadjuvant Immunotherapy Protocols is reshaping the global market by incorporating immune checkpoint inhibitors before surgical intervention for locally advanced disease. This strategic approach aims to downstage tumors and eliminate micrometastases, offering superior event-free survival rates compared to traditional chemoradiation pathways. Clinical adoption is accelerating as new data confirms that perioperative immunotherapy improves outcomes without delaying curative surgeries; according to the Washington University School of Medicine in April 2025, patients treated with pembrolizumab plus standard care achieved a median cancer-free survival of 51.8 months, compared to 30.4 months for those receiving standard care alone.

Simultaneously, the Adoption of Therapeutic De-escalation for HPV-Associated Cases is gaining traction, driven by the goal of reducing treatment-related morbidity in patients with favorable prognoses. Oncologists are increasingly using biomarkers to identify candidates for reduced-intensity radiation and chemotherapy, thereby minimizing long-term toxicities like dysphagia while preserving high cure rates. This personalized approach is vital as virus-driven malignancies rise relative to tobacco-related cases; the Centers for Disease Control and Prevention reported in December 2025 that approximately 49,908 new cancers are detected annually in HPV-associated regions, highlighting the growing market for these refined, organ-preserving regimens.

Key Market Players

  • Johnson & Johnson
  • Cipla Ltd
  • Abbott Laboratories Inc
  • AbbVie Inc
  • Merck KGaA
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Lupin Ltd
  • Pfizer Inc

Report Scope

In this report, the Global Laryngeal Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Laryngeal Cancer Therapeutics Market, By Product

  • Biologics
  • Small Molecules

Laryngeal Cancer Therapeutics Market, By End-User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Laryngeal Cancer Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Laryngeal Cancer Therapeutics Market.

Available Customizations:

Global Laryngeal Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Laryngeal Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Biologics, Small Molecules)
    • 5.2.2. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Laryngeal Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End-User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Laryngeal Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End-User
    • 6.3.2. Canada Laryngeal Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End-User
    • 6.3.3. Mexico Laryngeal Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End-User

7. Europe Laryngeal Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End-User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End-User
    • 7.3.2. France Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End-User
    • 7.3.3. United Kingdom Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End-User
    • 7.3.4. Italy Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End-User
    • 7.3.5. Spain Laryngeal Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End-User

8. Asia Pacific Laryngeal Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End-User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End-User
    • 8.3.2. India Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End-User
    • 8.3.3. Japan Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End-User
    • 8.3.4. South Korea Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End-User
    • 8.3.5. Australia Laryngeal Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End-User

9. Middle East & Africa Laryngeal Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End-User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Laryngeal Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End-User
    • 9.3.2. UAE Laryngeal Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End-User
    • 9.3.3. South Africa Laryngeal Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End-User

10. South America Laryngeal Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End-User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Laryngeal Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End-User
    • 10.3.2. Colombia Laryngeal Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End-User
    • 10.3.3. Argentina Laryngeal Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Laryngeal Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Johnson & Johnson
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cipla Ltd
  • 15.3. Abbott Laboratories Inc
  • 15.4. AbbVie Inc
  • 15.5. Merck KGaA
  • 15.6. Bausch Health Companies Inc.
  • 15.7. Sun Pharmaceutical Industries Ltd
  • 15.8. Aurobindo Pharma Ltd
  • 15.9. Lupin Ltd
  • 15.10. Pfizer Inc

16. Strategic Recommendations

17. About Us & Disclaimer